Hashem B El-Serag

List of Publications by Year
in descending order

467 papers	67,824 citations	1040 113 h-index	764 249 g-index
478 all docs	478 docs citations	478 times ranked	49420 citing authors

#	Article	IF	Citations
1	Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology, 2007, 132, 2557-2576.	0.6	4,828
2	Hepatocellular Carcinoma. New England Journal of Medicine, 2011, 365, 1118-1127.	13.9	3,427
3	Rising Incidence of Hepatocellular Carcinoma in the United States. New England Journal of Medicine, 1999, 340, 745-750.	13.9	3,008
4	Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 2012, 142, 1264-1273.e1.	0.6	2,753
5	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	13.5	1,794
6	Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2014, 63, 871-880.	6.1	1,444
7	Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 477-491.e1.	0.6	1,133
8	Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology, 2004, 126, 460-468.	0.6	1,105
9	The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 2004, 24, 115-125.	1.8	1,054
10	Esophageal Carcinoma. New England Journal of Medicine, 2014, 371, 2499-2509.	13.9	1,051
11	Epidemiology of Hepatocellular Carcinoma. Hepatology, 2021, 73, 4-13.	3.6	1,007
12	Meta-Analysis: Obesity and the Risk for Gastroesophageal Reflux Disease and Its Complications. Annals of Internal Medicine, 2005, 143, 199.	2.0	1,002
13	Epidemiology of Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2013, 47, S2-S6.	1.1	996
14	Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1752-1763.	0.6	994
15	Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology, 2004, 127, S27-S34.	0.6	904
16	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 223-238.	8.2	867
17	The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update. Annals of Internal Medicine, 2003, 139, 817.	2.0	841
18	Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology, 2010, 138, 513-521.e6.	0.6	797

#	Article	IF	Citations
19	Burden of Gastric Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 534-542.	2.4	775
20	The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence. Clinical Gastroenterology and Hepatology, 2006, 4, 369-380.	2.4	740
21	Risk factors for cholangiocarcinoma. Hepatology, 2011, 54, 173-184.	3.6	736
22	Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology, 2017, 153, 996-1005.e1.	0.6	680
23	Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. Journal of Hepatology, 2004, 40, 472-477.	1.8	641
24	Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. Clinical Gastroenterology and Hepatology, 2012, 10, 1342-1359.e2.	2.4	634
25	Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2002, 35, S72-S78.	1.1	577
26	Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?. Hepatology, 2014, 60, 1767-1775.	3.6	536
27	Obesity Is an Independent Risk Factor for GERD Symptoms and Erosive Esophagitis. American Journal of Gastroenterology, 2005, 100, 1243-1250.	0.2	506
28	Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology, 2005, 128, 620-626.	0.6	499
29	Obesity: A Challenge to Esophagogastric Junction Integrity. Gastroenterology, 2006, 130, 639-649.	0.6	493
30	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 1828-1837.e2.	0.6	490
31	Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 124-131.e1.	2.4	471
32	Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology, 2004, 127, 1372-1380.	0.6	469
33	The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S206-S214.	0.4	465
34	Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Case-Control Study. Clinical Gastroenterology and Hepatology, 2007, 5, 1221-1228.	2.4	455
35	Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database. Hepatology, 2011, 54, 463-471.	3.6	454
36	The Epidemiology of Obesity. Gastroenterology Clinics of North America, 2010, 39, 1-7.	1.0	446

#	Article	IF	Citations
37	Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clinical Gastroenterology and Hepatology, 2015, 13, 2140-2151.	2.4	436
38	Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control, 2017, 24, 107327481772924.	0.7	400
39	Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointestinal Endoscopy, 2008, 67, 394-398.	0.5	392
40	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteranâ€™s Affairs Health Care System. BMC Medical Research Methodology, 2018, 18, 1.	1.4	390
41	Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. Journal of Hepatology, 2008, 49, 831-844.	1.8	364
42	Time Trends of Gastroesophageal Reflux Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2007, 5, 17-26.	2.4	362
43	Risk Factors for the Rising Rates of Primary Liver Cancer in the United States. Archives of Internal Medicine, 2000, 160, 3227.	4.3	354
44	Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Gastroenterology, 2011, 140, 1182-1188.e1.	0.6	349
45	Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. Journal of Hepatology, 2019, 71, 104-114.	1.8	344
46	Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology, 2010, 52, 132-141.	3.6	343
47	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology, 2017, 152, 812-820.e5.	0.6	339
48	Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus. American Journal of Gastroenterology, 2004, 99, 1877-1883.	0.2	331
49	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology, 2020, 159, 320-334.e27.	0.6	330
50	Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology, 2001, 33, 62-65.	3.6	321
51	Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology, 2016, 64, 130-137.	3.6	319
52	Global epidemiology and burden of HCV infection and HCV-related disease. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 122-132.	8.2	317
53	Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus. JAMA - Journal of the American Medical Association, 2007, 297, 2010.	3.8	294
54	Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease, 2001, 5, 87-107.	1.0	291

#	Article	IF	Citations
55	Central Adiposity Is Associated With Increased Risk of Esophageal Inflammation, Metaplasia, and Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2013, 11, 1399-1412.e7.	2.4	287
56	Epidemiology of hepatocellular carcinoma in USA. Hepatology Research, 2007, 37, S88-94.	1.8	283
57	Hepatocellular carcinoma and hepatitis C in the United States. Hepatology, 2002, 36, S74-S83.	3.6	281
58	Utilization of Surveillance for Hepatocellular Carcinoma Among Hepatitis C Virusâ€“Infected Veterans in the United States. Annals of Internal Medicine, 2011, 154, 85.	2.0	272
59	Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology, 2004, 39, 798-803.	3.6	263
60	Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States. American Journal of Gastroenterology, 2013, 108, 1314-1321.	0.2	263
61	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology, 2015, 149, 340-349.e2.	0.6	262
62	The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. American Journal of Gastroenterology, 2001, 96, 2462-2467.	0.2	256
63	AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology, 2020, 159, 739-758.e4.	0.6	254
64	Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology, 2009, 49, 116-123.	3.6	253
65	Lifestyle Intervention in Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 175-182.e3.	2.4	251
66	HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology, 2014, 60, 98-105.	3.6	248
67	Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes. Gastroenterology, 2009, 136, 1601-1608.	0.6	247
68	Obesity increases oesophageal acid exposure. Gut, 2007, 56, 749-755.	6.1	246
69	Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut, 2014, 63, 1229-1237.	6.1	242
70	Gastroesophageal reflux among different racial groups in the United Statesâ¨†. Gastroenterology, 2004, 126, 1692-1699.	0.6	239
71	Hepatocellular carcinoma and hepatitis C in the United States. Hepatology, 2002, 36, s74-s83.	3.6	237
72	Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based Case?Control Study. American Journal of Gastroenterology, 2007, 102, 1016-1021.	0.2	235

#	Article	IF	Citations
73	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161, 1657-1669.	0.6	229
74	Symptomatic reflux disease: the present, the past and the future. Gut, 2014, 63, 1185-1193.	6.1	226
75	Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 2002, 123, 476-482.	0.6	224
76	Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. Journal of Hepatology, 2006, 44, 158-166.	1.8	223
77	Temporal Trends of Nonalcoholic Fatty Liver Diseaseâ€"Related Hepatocellular Carcinoma in the Veteran Affairs Population. Clinical Gastroenterology and Hepatology, 2015, 13, 594-601.e1.	2.4	215
78	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 2020, 158, 1822-1830.	0.6	202
79	Temporal Trends (1973â€"1997) in Survival of Patients With Esophageal Adenocarcinoma in The United States: A Glimmer of Hope?. American Journal of Gastroenterology, 2003, 98, 1627-1633.	0.2	197
80	Abdominal Obesity and the Risk of Barrett's Esophagus. American Journal of Gastroenterology, 2005, 100, 2151-2156.	0.2	197
81	Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology, 2018, 16, 992-1002.e6.	2.4	189
82	A Comparison of Trends in the Incidence of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the United States. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1198-1203.	1.1	188
83	Longâ€Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology, 2020, 71, 44-55.	3.6	188
84	Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology, 2001, 121, 1294-1299.	0.6	187
85	Lansoprazole Treatment of Patients With Chronic Idiopathic Laryngitis: A Placebo-Controlled Trial. American Journal of Gastroenterology, 2001, 96, 979-983.	0.2	186
86	Improved Survival After Variceal Hemorrhage Over An 11-Year Period in The Department of Veterans Affairs. American Journal of Gastroenterology, 2000, 95, 3566-3573.	0.2	178
87	AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology, 2020, 158, 693-702.	0.6	177
88	Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus. Gastroenterology, 2010, 138, 2260-2266.	0.6	172
89	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 808-819.	3.6	170
90	Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology, 2002, 36, 1439-1445.	3.6	169

#	Article	IF	Citations
91	Burden of Pancreatic Cancer: From Epidemiology to Practice. Clinical Gastroenterology and Hepatology, 2021, 19, 876-884.	2.4	166
92	Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism, 2022, 34, 969-977.e2.	7.2	163
93	Gastric Cancer as Preventable Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1833-1843.	2.4	162
94	Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology, 2002, 36, 1439-1445.	3.6	159
95	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 61-71.e15.	2.4	159
96	A New Laboratory-Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients With Hepatitis C and Cirrhosis. Gastroenterology, 2014, 146, 1249-1255.e1.	0.6	156
97	The Effect of HIV Coinfection on the Risk of Cirrhosis and Hepatocellular Carcinoma in U.S. Veterans with Hepatitis C. American Journal of Gastroenterology, 2005, 100, 56-63.	0.2	148
98	Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2009, 7, 1299-1304.	2.4	147
99	Diabetes increases the risk of acute hepatic failure. Gastroenterology, 2002, 122, 1822-1828.	0.6	142
100	Cirrhosis and Hepatocellular Carcinoma in HIV-Infected Veterans With and Without the Hepatitis C Virus. Archives of Internal Medicine, 2004, 164, 2349.	4.3	138
101	Is there a true "shift" to the right colon in the incidence of colorectal cancer?. American Journal of Gastroenterology, 2003, 98, 1400-1409.	0.2	137
102	Characteristics of Children Receiving Proton Pump Inhibitors Continuously for Up to 11 Years Duration. Journal of Pediatrics, 2007, 150, 262-267.e1.	0.9	136
103	Trends in the Burden of Nonalcoholic Fatty Liver Disease inÂaÂUnited States Cohort of Veterans. Clinical Gastroenterology and Hepatology, 2016, 14, 301-308.e2.	2.4	136
104	Anthropometric correlates of intragastric pressure. Scandinavian Journal of Gastroenterology, 2006, 41, 887-891.	0.6	134
105	The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. Gastroenterology, 2012, 143, 70-77.	0.6	133
106	Human Immunodeficiency Virusâ€“Associated Squamous Cell Cancer of the Anus: Epidemiology and Outcomes in the Highly Active Antiretroviral Therapy Era. Journal of Clinical Oncology, 2008, 26, 474-479.	0.8	130
107	Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clinical Gastroenterology and Hepatology, 2015, 13, 1616-1624.	2.4	128
108	Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic LiverÂDisease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2016, 14, 191-202.e4.	2.4	126

#	Article	IF	Citations
109	Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut, 2014, 63, 220.2-229.	6.1	124
110	Epidemiology of Hepatocellular Carcinoma in Hispanics in the United States. Archives of Internal Medicine, 2007, 167, 1983.	4.3	123
111	Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 1220-1228.e4.	2.4	122
112	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. Journal of Hepatology, 2018, 69, 278-285.	1.8	120
113	Role of obesity in GORD-related disorders. Gut, 2008, 57, 281-284.	6.1	119
114	Gastroesophageal Reflux and Asthma in Children: A Systematic Review. Pediatrics, 2010, 125, e925-e930.	1.0	119
115	Rising Prevalence of Hepatitis C Virus Infection Among Patients Recently Diagnosed With Hepatocellular Carcinoma in the United States. Journal of Clinical Gastroenterology, 2002, 35, 266-269.	1.1	116
116	Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. Journal of Hepatology, 2016, 65, 1148-1154.	1.8	114
117	Genetic Variants of Glutathione S-Transferase as Possible Risk Factors for Hepatocellular Carcinoma: A HuGE Systematic Review and Meta-Analysis. American Journal of Epidemiology, 2008, 167, 377-389.	1.6	113
118	Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut, 2016, 65, 1252-1260.	6.1	113
119	Surveillance for hepatocellular carcinoma: in whom and how?. Therapeutic Advances in Gastroenterology, 2011, 4, 5-10.	1.4	111
120	Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting. American Journal of Gastroenterology, 2015, 110, 10-14.	0.2	110
121	The Epidemiology of Hepatocellular Carcinoma in the USA. Current Gastroenterology Reports, 2019, 21, 17.	1.1	110
122	Oral contraception and the risk of hepatocellular carcinoma. Journal of Hepatology, 2007, 47, 506-513.	1.8	106
123	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clinical Gastroenterology and Hepatology, 2017, 15, 273-281.e1.	2.4	106
124	Utilization of Screening for Hepatocellular Carcinoma in the United States. Journal of Clinical Gastroenterology, 2007, 41, 777-782.	1.1	105
125	Missed Opportunities to Initiate Endoscopic Evaluation for Colorectal Cancer Diagnosis. American Journal of Gastroenterology, 2009, 104, 2543-2554.	0.2	104
126	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. Journal of Hepatology, 2017, 66, 355-362.	1.8	104

#	Article	IF	Citations
127	The epidemic of esophageal adenocarcinoma. Gastroenterology Clinics of North America, 2002, 31, 421-440.	1.0	103
128	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. Journal of Hepatology, 2019, 70, 639-647.	1.8	101
129	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.4	99
130	Association Between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux. JAMA - Journal of the American Medical Association, 2017, 318, 939.	3.8	97
131	Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 119-129.	0.6	94
132	Evaluation for liver transplantation: Adherence to AASLD referral guidelines in a large veterans affairs center. Liver Transplantation, 2005, 11, 1370-1378.	1.3	93
133	The Use of Screening Colonoscopy for Patients Cared for by the Department of Veterans Affairs. Archives of Internal Medicine, 2006, 166, 2202.	4.3	90
134	Age at Onset of GERD Symptoms Predicts Risk of Barrett's Esophagus. American Journal of Gastroenterology, 2013, 108, 915-922.	0.2	88
135	Secular Trends in the Incidence of Cholangiocarcinoma in the USA and the Impact of Misclassification. Digestive Diseases and Sciences, 2014, 59, 3103-3110.	1.1	87
136	Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Journal of Hepatology, 2012, 56, 320-325.	1.8	86
137	Childhood GERD is a Risk Factor for GERD in Adolescents and Young Adults. American Journal of Gastroenterology, 2004, 99, 806-812.	0.2	85
138	Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States. Hepatology, 2011, 53, 737-745.	3.6	85
139	Racial Disparities in Utilization of Liver Transplantation for Hepatocellular Carcinoma in the United States, 1998â€“2002. American Journal of Gastroenterology, 2008, 103, 120-127.	0.2	84
140	Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut, 2011, 60, 992-997.	6.1	84
141	Waist-to-Hip Ratio, but Not Body Mass Index, Is Associated With an Increased Risk of Barrett's Esophagus in White Men. Clinical Gastroenterology and Hepatology, 2013, 11, 373-381.e1.	2.4	84
142	Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans. American Journal of Gastroenterology, 2014, 109, 1427-1435.	0.2	84
143	Quality Indicators for the Management of Barrettâ€™s Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. Gastroenterology, 2015, 149, 1599-1606.	0.6	81
144	Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. Journal of Hepatology, 2020, 73, 1425-1433.	1.8	81

#	Article	IF	Citations
145	Survival of Colorectal Cancer Patients Hospitalized in The Veterans Affairs Health Care System. American Journal of Gastroenterology, 2003, 98, 1186-1192.	0.2	80
146	Fundoplication and the Risk of Esophageal Cancer in Gastroesophageal Reflux Disease: A Veterans Affairs Cohort Study. American Journal of Gastroenterology, 2005, 100, 1002-1008.	0.2	80
147	The Association Between Barrettâ€™s Esophagus and Helicobacter pylori Infection: A Metaâ€Analysis. Helicobacter, 2012, 17, 163-175.	1.6	79
148	Surgical Volume and Long-Term Survival Following Surgery for Colorectal Cancer in the Veterans Affairs Health-Care System. American Journal of Gastroenterology, 2004, 99, 668-675.	0.2	78
149	Prevalence of Endoscopic Findings of Erosive Esophagitis in Children: A Populationâ€based Study. Journal of Pediatric Gastroenterology and Nutrition, 2008, 47, 141-146.	0.9	78
150	Dietary quality and the colonic mucosaâ€“associated gut microbiome in humans. American Journal of Clinical Nutrition, 2019, 110, 701-712.	2.2	78
151	Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2012, 46, 71-77.	1.1	75
152	Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology, 2013, 58, 538-545.	3.6	75
153	Esophageal Carcinoma. New England Journal of Medicine, 2015, 372, 1470-1473.	13.9	73
154	Helicobacter pylori -Negative Gastritis: Prevalence and Risk Factors. American Journal of Gastroenterology, 2013, 108, 65-71.	0.2	72
155	Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Digestive Diseases and Sciences, 2016, 61, 1714-1720.	1.1	72
156	Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. Journal of Hepatology, 2005, 42, 309-314.	1.8	71
157	Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study. American Journal of Gastroenterology, 2011, 106, 483-491.	0.2	71
158	Circulating Inflammatory Cytokines and Adipokines Are Associated With Increased Risk of Barrett's Esophagus: A Caseâ€“Control Study. Clinical Gastroenterology and Hepatology, 2014, 12, 229-238.e3.	2.4	71
159	Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1207-1217.e4.	2.4	71
160	Endoscopic Manifestations of Gastroesophageal Reflux Disease in Patients Between 18 Months and 25 Years Without Neurological Deficits. American Journal of Gastroenterology, 2002, 97, 1635-1639.	0.2	70
161	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	3.6	70
162	GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology, 2022, 75, 541-549.	3.6	70

#	Article	IF	Citations
163	The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointestinal Endoscopy, 2006, 64, 671-675.	0.5	69
164	Higher serum testosterone is associated with increased risk of advanced hepatitis Câ€“related liver disease in males. Hepatology, 2012, 55, 759-768.	3.6	69
165	Early outpatient followâ€up and 30â€day outcomes in patients hospitalized with cirrhosis. Hepatology, 2016, 64, 569-581.	3.6	69
166	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 638-651.	8.2	69
167	Epidemiology of Non-Erosive Reflux Disease. Digestion, 2008, 78, 6-10.	1.2	68
168	Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Molecular Carcinogenesis, 2013, 52, 139-147.	1.3	68
169	Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival. Clinical Gastroenterology and Hepatology, 2007, 5, 508-512.	2.4	67
170	Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virusâ€infected patients. Hepatology, 2014, 60, 1871-1878.	3.6	67
171	Menopausal hormone therapy and the risk of esophageal and gastric cancer. International Journal of Cancer, 2017, 140, 1693-1699.	2.3	67
172	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. Journal of Viral Hepatitis, 2019, 26, 596-602.	1.0	67
173	A Multibiomarker Risk Score Helps Predict Risk for Barrettâ€™sÂEsophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 1267-1271.	2.4	66
174	Gastric Microbiota in Helicobacter pylori-Negative and -Positive Gastritis Among High Incidence of Gastric Cancer Area. Cancers, 2019, 11, 504.	1.7	66
175	Gastro-oesophageal reflux disease. Nature Reviews Disease Primers, 2021, 7, 55.	18.1	66
176	Underdiagnosis of Lynch Syndrome Involves More Than Family History Criteria. Clinical Gastroenterology and Hepatology, 2010, 8, 523-529.	2.4	65
177	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology, 2022, 75, 1420-1428.	3.6	65
178	The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?. American Journal of Gastroenterology, 2003, 98, 2535-2542.	0.2	63
179	Noncardia Gastric Adenocarcinoma Remains an Important and Deadly Cancer in the United States: Secular Trends in Incidence and Survival. American Journal of Gastroenterology, 2006, 101, 2485-2492.	0.2	63
180	Association between Helicobacter pylori and Barrett's Esophagus: A Caseâ€“Control Study. American Journal of Gastroenterology, 2014, 109, 357-368.	0.2	63

#	Article	IF	Citations
181	Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clinical Gastroenterology and Hepatology, 2018, 16, 1677-1678.	2.4	63
182	Psychosocial Factors Are the Most Common Contraindications for Antiviral Therapy at Initial Evaluation in Veterans With Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2004, 38, 530-534.	1.1	62
183	Prevalence of Barrettâ€™s Esophagus in Asian Countries: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 1907-1918.	2.4	60
184	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clinical Infectious Diseases, 2016, 63, 291-299.	2.9	60
185	Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. International Journal of Epidemiology, 2018, 47, 966-975.	0.9	59
186	Gastric mucosal microbiota in a Mongolian population with gastric cancer and precursor conditions. Alimentary Pharmacology and Therapeutics, 2020, 51, 770-780.	1.9	58
187	Preparing for the NASH Epidemic: A Call to Action. Gastroenterology, 2021, 161, 1030-1042.e8.	0.6	58
188	Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. American Journal of Gastroenterology, 2018, 113, 1148-1155.	0.2	57
189	The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clinical Gastroenterology and Hepatology, 2023, 21, 415-423.e4.	2.4	56
190	Characteristics of Intestinal Metaplasia in The Gastric Cardia. American Journal of Gastroenterology, 1999, 94, 622-627.	0.2	55
191	Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases. Hepatology, 2011, 53, 1060-1061.	3.6	54
192	The Incidence and Prevalence of Inflammatory Bowel Disease Among U.S. Veterans. Inflammatory Bowel Diseases, 2013, 19, 1059-1064.	0.9	54
193	Outcomes of surgical fundoplication in children. Clinical Gastroenterology and Hepatology, 2004, 2, 978-984.	2.4	53
194	Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis Câ€“Infected Patients. Clinical Gastroenterology and Hepatology, 2012, 10, 428-433.	2.4	53
195	Leadership During Crisis: Lessons and Applications from the COVID-19 Pandemic. Gastroenterology, 2020, 159, 809-812.	0.6	51
196	Artificial intelligence in gastroenterology: A state-of-the-art review. World Journal of Gastroenterology, 2021, 27, 6794-6824.	1.4	50
197	Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology, 2011, 53, 42-52.	3.6	49
198	Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: Effect of patient and nonpatient factors. Hepatology, 2013, 57, 1858-1868.	3.6	49

#	Article	IF	Citations
199	Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. American Journal of Gastroenterology, 2017, 112, 1287-1297.	0.2	49
200	Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). American Journal of Gastroenterology, 2003, 98, 471-477.	0.2	48
201	Physical and Psychosocial Contributors to Quality of Life in Veterans With Hepatitis C Not on Antiviral Therapy. Journal of Clinical Gastroenterology, 2005, 39, 731-736.	1.1	48
202	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients, 2019, 11, 613.	1.7	48
203	Systematic review with metaâ€analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Alimentary Pharmacology and Therapeutics, 2020, 52, 20-36.	1.9	48
204	The Prevalence of <scp>H</scp>elicobacter pylori Remains High in African American and Hispanic Veterans. Helicobacter, 2015, 20, 305-315.	1.6	47
205	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2018, 16, 252-259.	2.4	47
206	The effects of sustained virological response to directâ€acting antiâ€viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Alimentary Pharmacology and Therapeutics, 2019, 49, 1442-1447.	1.9	47
207	Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology, 2020, 72, 1242-1252.	3.6	47
208	Rational HCC screening approaches for patients with NAFLD. Journal of Hepatology, 2022, 76, 195-201.	1.8	47
209	No Significant Effects of Smoking or Alcohol Consumption on Risk of Barrettâ€™s Esophagus. Digestive Diseases and Sciences, 2014, 59, 108-116.	1.1	46
210	Level of Î±-Fetoprotein Predicts Mortality Among Patients With Hepatitis Câ€“Related Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2011, 9, 989-994.	2.4	45
211	Statin Use Reduces Risk of Esophageal Adenocarcinoma in US Veterans With Barrettâ€™s Esophagus: A Nested Case-Control Study. Gastroenterology, 2015, 149, 1392-1398.	0.6	45
212	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Network Open, 2020, 3, e2023780.	2.8	45
213	Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing. Medical Care, 2016, 54, e9-e14.	1.1	44
214	Postoperative 30-day Mortality Following Surgical Resection for Colorectal Cancer in Veterans: Changes in the Right Direction. Digestive Diseases and Sciences, 2005, 50, 1722-1728.	1.1	43
215	The Impact of HIV Viral Control on the Incidence of HIV-Associated Anal Cancer. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 631-638.	0.9	43
216	Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. Journal of the National Cancer Institute, 2018, 110, 49-56.	3.0	43

#	Article	IF	Citations
217	Endoscopic and Surgical Therapy for Intrahepatic Cholangiocarcinoma in the United States. Journal of Clinical Gastroenterology, 2007, 41, 911-917.	1.1	42
218	The Quality of Care Provided to Patients With Varices in the Department of Veterans Affairs. American Journal of Gastroenterology, 2014, 109, 934-940.	0.2	42
219	Celiac sprue among US military veterans: associated disorders and clinical manifestations. Digestive Diseases and Sciences, 1999, 44, 966-972.	1.1	40
220	Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clinical Gastroenterology and Hepatology, 2015, 13, 1521-1531.e3.	2.4	40
221	Clinical Manifestations of Helicobacter pyloriâ€“Negative Gastritis. Clinical Gastroenterology and Hepatology, 2017, 15, 1037-1046.e3.	2.4	40
222	Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology, 2018, 16, 1531-1532.	2.4	40
223	Determinants of Gastroesophageal Reflux Disease in Adults With a History of Childhood Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology, 2007, 5, 696-701.	2.4	39
224	Epidemiology and outcomes of hepatitis C infection in elderly <scp>US</scp> Veterans. Journal of Viral Hepatitis, 2016, 23, 687-696.	1.0	39
225	Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans. Digestive Diseases and Sciences, 2010, 55, 190-195.	1.1	38
226	Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology, 2010, 52, 403-407.	3.6	37
227	Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surgery for Obesity and Related Diseases, 2017, 13, 28-34.	1.0	37
228	Factors Associated With Recurrence of Barrettâ€™s Esophagus After Radiofrequency Ablation. Clinical Gastroenterology and Hepatology, 2019, 17, 65-72.e5.	2.4	37
229	Secular Trends in the Use, Quality, and Outcomes of Gastrectomy for Noncardia Gastric Cancer in the United States. Annals of Surgical Oncology, 2007, 14, 2519-2527.	0.7	36
230	Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1886-1893.e5.	2.4	36
231	Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology, 2023, 77, 997-1005.	3.6	36
232	Obesity and Disease of the Esophagus and Colon. Gastroenterology Clinics of North America, 2005, 34, 63-82.	1.0	35
233	Reducing referral delays in colorectal cancer diagnosis: is it about how you ask?. BMJ Quality and Safety, 2010, 19, e27-e27.	1.8	35
234	Obesity and hepatocellular carcinoma: Hype and reality. Hepatology, 2014, 60, 779-781.	3.6	35

#	Article	IF	Citations
235	Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPÎ±-p300 Axis. Cell Reports, 2018, 24, 1597-1609.	2.9	35
236	Geographic variation within the United States in the incidence of hepatocellular carcinoma. Journal of Clinical Epidemiology, 2003, 56, 487-493.	2.4	34
237	Automated Identification of Surveillance Colonoscopy in Inflammatory Bowel Disease Using Natural Language Processing. Digestive Diseases and Sciences, 2013, 58, 936-941.	1.1	34
238	Risk Factors for Barrettâ€™s Esophagus Compared Between African Americans and Non-Hispanic Whites. American Journal of Gastroenterology, 2014, 109, 1870-1880.	0.2	34
239	Statin Use Is Associated With a Decreased Risk of Barrettâ€™s Esophagus. Gastroenterology, 2014, 147, 314-323.	0.6	34
240	The Updated Model: An Adjusted Serum Alpha-Fetoproteinâ€“Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology, 2015, 149, 1986-1987.	0.6	34
241	Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. American Journal of Gastroenterology, 2020, 115, 381-387.	0.2	34
242	Prevalence of Barrettâ€™s esophagus and performance of societalÂscreening guidelines in an unreferred primary care population of U.S. veterans. Gastrointestinal Endoscopy, 2021, 93, 409-419.e1.	0.5	34
243	Gene expression in Barrett's esophagus: Laser capture versus whole tissue. Scandinavian Journal of Gastroenterology, 2009, 44, 787-795.	0.6	32
244	Risk Factors for Cirrhosis in Contemporary Hepatology Practicesâ€”Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology, 2020, 159, 376-377.	0.6	32
245	Determinants of Medical System Delay in the Diagnosis of Colorectal Cancer Within the Veteran Affairs Health System. Digestive Diseases and Sciences, 2010, 55, 1434-1441.	1.1	31
246	Outcome of Erosive Reflux Esophagitis After Nissen Fundoplication. American Journal of Gastroenterology, 1999, 94, 1771-1776.	0.2	30
247	Cost-Effectiveness and Diagnostic Effectiveness Analyses of Multiple Algorithms for the Diagnosis of Lynch Syndrome. Digestive Diseases and Sciences, 2014, 59, 2913-2926.	1.1	30
248	Barrett's Esophagus Suspected at Endoscopy but No Specialized Intestinal Metaplasia on Biopsy, What's Next?. American Journal of Gastroenterology, 2014, 109, 178-182.	0.2	30
249	Patient-Reported Attributions for Missed Colonoscopy Appointments in Two Large Healthcare Systems. Digestive Diseases and Sciences, 2016, 61, 1853-1861.	1.1	30
250	Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. Journal of Viral Hepatitis, 2018, 25, 543-551.	1.0	30
251	Preparing for the NASH Epidemic: A Call to Action. Diabetes Care, 2021, 44, 2162-2172.	4.3	30
252	Routine Polypectomy for Colorectal Polyps and Ablation for Barrett's Esophagus Are Intellectually the Same. Gastroenterology, 2011, 140, 386-388.	0.6	29

#	Article	IF	Citations
253	Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clinical Gastroenterology and Hepatology, 2019, 17, 2117-2125.e3.	2.4	29
254	Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrettâ€™s Esophagus. Digestive Diseases and Sciences, 2010, 55, 3404-3407.	1.1	28
255	Î±-Fetoprotein in Hepatocellular Carcinoma Surveillance: Mend It but Do Not End It. Clinical Gastroenterology and Hepatology, 2013, 11, 441-443.	2.4	28
256	Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2016, 111, 1528-1535.	0.2	28
257	Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Digestive Diseases and Sciences, 2017, 62, 2713-2718.	1.1	28
258	The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A retrospective cohort Study of united States Veterans. American Journal of Gastroenterology, 2018, 113, 1310.	0.2	28
259	Temporal Trends in New and Recurrent Esophageal Strictures in Department of Veterans Affairs. American Journal of Gastroenterology, 2006, 101, 1727-1733.	0.2	27
260	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Digestive Diseases and Sciences, 2017, 62, 526-533.	1.1	27
261	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. American Journal of Gastroenterology, 2019, 114, 530-532.	0.2	27
262	Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Ageâ€“Periodâ€“Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 88-94.	1.1	27
263	Incidence and Survival of Colorectal Cancer Among Hispanics in the United States: A Population-Based Study. Digestive Diseases and Sciences, 2013, 58, 2052-2060.	1.1	26
264	Ethnic Variations in the Occurrence of Gastroesophageal Cancers. Journal of Clinical Gastroenterology, 1999, 28, 135-139.	1.1	26
265	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1289-1299.	3.6	26
266	Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Reviews in Gastroenterological Disorders, 2003, 3 Suppl 2, S3-11.	0.6	26
267	Survival in hepatitis C and HIV co-infection: A cohort study of hospitalized veterans. Clinical Gastroenterology and Hepatology, 2005, 3, 175-183.	2.4	25
268	The Use of Cytokeratin Stain to Distinguish Barrettâ€™s Esophagus from Contiguous Tissues: A Systematic Review. Digestive Diseases and Sciences, 2007, 52, 1345-1354.	1.1	25
269	Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus. Gastrointestinal Endoscopy, 2012, 76, 743-755.	0.5	25
270	Fat Mass by Bioelectrical Impedance Analysis is not Associated With Increased Risk of Barrett Esophagus. Journal of Clinical Gastroenterology, 2014, 48, 218-223.	1.1	25

#	Article	IF	Citations
271	The Incidence of Esophageal Adenocarcinoma in a National Veterans Cohort With Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2014, 109, 1862-1868.	0.2	25
272	Prior Diagnosis of Barrettâ€™s Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Digestive Diseases and Sciences, 2018, 63, 3112-3119.	1.1	25
273	Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 657-665.e13.	2.4	25
274	Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes and Control, 2021, 32, 317-325.	0.8	25
275	Preparing for the NASH epidemic: A call to action. Metabolism: Clinical and Experimental, 2021, 122, 154822.	1.5	25
276	The big burden of obesity. Gastrointestinal Endoscopy, 2009, 70, 752-757.	0.5	24
277	Barrett's esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study. Gastrointestinal Endoscopy, 2011, 73, 875-880.	0.5	24
278	Sex and Racial DisparityÂin Incidence ofÂEsophageal Adenocarcinoma: Observations and Explanations. Clinical Gastroenterology and Hepatology, 2016, 14, 330-332.	2.4	24
279	Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clinical Gastroenterology and Hepatology, 2016, 14, 1678-1680.	2.4	23
280	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2021, 66, 2439-2451.	1.1	23
281	Cholangiocarcinoma: The â€œOtherâ€•Liver Cancer on the Rise. American Journal of Gastroenterology, 2002, 97, 3199-3200.	0.2	22
282	Inflammatory Bowel Disease Characteristics and Treatment in Hispanics and Caucasians. Digestive Diseases and Sciences, 2011, 56, 1476-1481.	1.1	22
283	Opportunities for Preventing Esophageal Adenocarcinoma. Cancer Prevention Research, 2016, 9, 828-834.	0.7	22
284	Helicobacter pylori Infection. New England Journal of Medicine, 2019, 381, 587-589.	13.9	22
285	Missed Opportunities for Screening and Surveillance of Barrettâ€™s Esophagus in Veterans with Esophageal Adenocarcinoma. Digestive Diseases and Sciences, 2019, 64, 367-372.	1.1	22
286	Gastric microbiota and Helicobacter pylori in Indonesian population. Helicobacter, 2020, 25, e12695.	1.6	22
287	Transarterial bland versus chemoembolization forÂhepatocellular carcinoma: rethinking aÂgoldÂstandard. Journal of Surgical Research, 2016, 200, 552-559.	0.8	21
288	A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women. Cancer Prevention Research, 2019, 12, 237-246.	0.7	21

#	Article	IF	Citations
289	Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis*. Inflammatory Bowel Diseases, 2012, 18, 1011-1017.	0.9	20
290	Choosing Wisely and the Perceived Drivers of Endoscopy Use. Clinical Gastroenterology and Hepatology, 2013, 11, 753-755.	2.4	20
291	Nonsteroidal Anti-inflammatory Drugs and the Risk of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 1832-1839.e6.	2.4	20
292	Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Womenâ€™s Health Initiative Study. Journal of Clinical Medicine, 2018, 7, 197.	1.0	20
293	Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Digestive Diseases and Sciences, 2020, 65, 2403-2411.	1.1	20
294	European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut, 2021, 70, 1-2.	6.1	20
295	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. Journal of Hepatology, 2022, 76, 294-301.	1.8	20
296	Cholangiocarcinoma: the â€œotherâ€•liver cancer on the rise. American Journal of Gastroenterology, 2002, 97, 3199-3200.	0.2	19
297	Translational Research: The Study of Community Effectiveness in Digestive and Liver Disorders. Gastroenterology, 2007, 132, 8-10.	0.6	19
298	Patient Experiences with Surveillance Endoscopy: A Qualitative Study. Digestive Diseases and Sciences, 2014, 59, 1378-1385.	1.1	19
299	External Validation of the Michigan Barrettâ€™s Esophagus Prediction Tool. Clinical Gastroenterology and Hepatology, 2017, 15, 1124-1126.	2.4	19
300	Sleep Duration and Risk of Liver Cancer in Postmenopausal Women: The Women's Health Initiative Study. Journal of Women's Health, 2017, 26, 1270-1277.	1.5	19
301	The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1423-1428.	0.9	19
302	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Digestive Diseases and Sciences, 2021, 66, 912-916.	1.1	19
303	Habitual Sleep Duration and the Colonic Mucosa-Associated Gut Microbiota in Humansâ€”A Pilot Study. Clocks & Sleep, 2021, 3, 387-397.	0.9	19
304	Assessment of disease specific knowledge and health-related quality of life among United States military veterans with inflammatory bowel disease. World Journal of Gastroenterology, 2015, 21, 6001-6007.	1.4	19
305	Is there a true â€œshiftâ€•to the right colon in the incidence of colorectal cancer?. American Journal of Gastroenterology, 2003, 98, 1400-1409.	0.2	18
306	Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory Data. Digestive Diseases and Sciences, 2010, 55, 3241-3251.	1.1	18

#	Article	IF	Citations
307	Hepatocellular Carcinoma Screening Practices in the Department of Veterans Affairs: Findings from a National Facility Survey. Digestive Diseases and Sciences, 2013, 58, 3117-3126.	1.1	18
308	Human papillomavirus and the risk of Barrett's esophagus. Ecological Management and Restoration, 2013, 26, 517-521.	0.2	18
309	Limited Life Expectancy Among a Subgroup of Medicare Beneficiaries Receiving Screening Colonoscopies. Clinical Gastroenterology and Hepatology, 2014, 12, 443-450.e1.	2.4	18
310	Hepatocellular carcinoma surveillance: The road ahead. Hepatology, 2017, 65, 771-773.	3.6	18
311	Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Digestive Diseases and Sciences, 2018, 63, 1551-1557.	1.1	18
312	Alcohol use alters the colonic mucosaâ€“associated gut microbiota in humans. Nutrition Research, 2020, 83, 119-128.	1.3	18
313	Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis. Helicobacter, 2021, 26, e12790.	1.6	18
314	The Performance of Process Measures in Hepatitis C. American Journal of Gastroenterology, 2012, 107, 1512-1521.	0.2	17
315	Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. European Journal of Cancer, 2017, 75, 41-46.	1.3	17
316	Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1684-1693.	1.4	17
317	Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population. Clinical Gastroenterology and Hepatology, 2021, 19, 269-276.e3.	2.4	17
318	Surveillance for Hepatocellular Carcinoma: Long Way to Achieve Effectiveness. Digestive Diseases and Sciences, 2012, 57, 3050-3051.	1.1	16
319	Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. Clinical Gastroenterology and Hepatology, 2012, 10, 1270-1277.e3.	2.4	16
320	Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy andÂEffectiveness. Clinical Gastroenterology and Hepatology, 2014, 12, 1381-1383.	2.4	16
321	The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2017, 112, 1049-1055.	0.2	16
322	Factors That Contribute to Indeterminate Results From theÂQuantiFERON-TB Gold In-Tube Test in Patients WithÂInflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1616-1621.e1.	2.4	16
323	How We Approach it: Treatment Options For Hepatocellular Carcinoma. American Journal of Gastroenterology, 2018, 113, 791-794.	0.2	16
324	WNT Signaling Pathway Gene Polymorphisms and Risk of Hepatic Fibrosis and Inflammation in HCV-Infected Patients. PLoS ONE, 2013, 8, e84407.	1.1	16

#	Article	IF	Citations
325	Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers. Scandinavian Journal of Gastroenterology, 2007, 42, 1158-1166.	0.6	15
326	Medical comorbidity and distress in patients with irritable bowel syndrome: The moderating role of age. Journal of Psychosomatic Research, 2016, 88, 48-53.	1.2	15
327	Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Digestive Diseases and Sciences, 2018, 63, 1173-1181.	1.1	15
328	A Systematic Review of the Effectiveness of Psychological Treatments for IBS in Gastroenterology Settings: Promising but in Need of Further Study. Digestive Diseases and Sciences, 2018, 63, 2189-2201.	1.1	15
329	Reply to: â€œGlobal trends in mortality from intrahepatic and extrahepatic cholangiocarcinomaâ€. Journal of Hepatology, 2019, 71, 1262-1263.	1.8	15
330	Recommendations for Successful Transition of Adolescents With Inflammatory Bowel Diseases to Adult Care. Clinical Gastroenterology and Hepatology, 2020, 18, 276-289.e2.	2.4	15
331	Management of the single liver nodule in a cirrhotic patient: a decision analysis model. Journal of Clinical Gastroenterology, 2005, 39, 152-9.	1.1	15
332	Is the length of newly diagnosed Barrettâ€™s esophagus decreasing? the experience of a VA health care system. Clinical Gastroenterology and Hepatology, 2004, 2, 296-300.	2.4	14
333	Surveillance in Barrett's Esophagus: Lessons from Behavioral Economics. Gastroenterology, 2009, 137, 763-765.	0.6	14
334	Use and Yield of Endoscopy in Patients With Uncomplicated Gastroesophageal Reflux Disorder. JAMA Internal Medicine, 2014, 174, 462.	2.6	14
335	Surveillance for Hepatocellular Carcinoma: Can We Focus on the Mission?. Clinical Gastroenterology and Hepatology, 2015, 13, 805-807.	2.4	14
336	A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. Cancer Epidemiology, 2016, 42, 115-123.	0.8	14
337	Republished: Symptomatic reflux disease: the present, the past and the future. Postgraduate Medical Journal, 2015, 91, 46-54.	0.9	13
338	A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Medicine, 2018, 7, 2180-2191.	1.3	13
339	Diabetes in relation to Barrettâ€™s esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrettâ€™s and Esophageal Adenocarcinoma Consortium. Cancer, 2019, 125, 4210-4223.	2.0	13
340	Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clinical Gastroenterology and Hepatology, 2021, 19, 1443-1450.e6.	2.4	13
341	Dietary Fatty Acid Intake and the Colonic Gut Microbiota in Humans. Nutrients, 2022, 14, 2722.	1.7	13
342	Hepatocellular cancer care: Cost is important but only one factor of disease burden. Journal of Hepatology, 2009, 50, 10-12.	1.8	12

#	Article	IF	Citations
343	Oral Bisphosphonates and the Risk of BarrettÊ¼s Esophagus: Caseâ€“Control Analysis of US Veterans. American Journal of Gastroenterology, 2013, 108, 1576-1583.	0.2	12
344	Inverse Association Between Gluteofemoral Obesity and Risk ofÂBarrettâ€™s Esophagus in a Pooled Analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1412-1419.e3.	2.4	12
345	Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2016, 14, 769-772.	2.4	12
346	Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clinical Gastroenterology and Hepatology, 2017, 15, 310-312.	2.4	12
347	Functional Dyspepsia and Duodenal Eosinophil Count and Degranulation: A Multiethnic US Veteran Cohort Study. Digestive Diseases and Sciences, 2021, 66, 3482-3489.	1.1	12
348	Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. Clinical Gastroenterology and Hepatology, 2014, 12, 327-333.e1.	2.4	11
349	Esophageal COX-2 Expression Is Increased in Barrettâ€™s Esophagus, Obesity, and Smoking. Digestive Diseases and Sciences, 2015, 60, 65-73.	1.1	11
350	Curbside Consultations: The Good, the Bad, and the Ugly. Clinical Gastroenterology and Hepatology, 2016, 14, 2-4.	2.4	11
351	Polymorphisms of 5-HTT LPR and GNÎ²3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. American Journal of Gastroenterology, 2017, 112, 903-909.	0.2	11
352	Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2017, 62, 607-614.	1.1	11
353	Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 1679-1687.	2.4	11
354	Increasing Incidence of Advanced Non-cardia Gastric Cancers Among Younger Hispanics in the USA. Digestive Diseases and Sciences, 2021, 66, 1669-1672.	1.1	11
355	Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. Journal of Family Practice, 2010, 59, S37-42.	0.2	11
356	Epidemiology of Gastroesophageal Reflux Disease. Progress in Surgery, 1997, 23, 20-36.	0.0	10
357	Is genomic evaluation feasible in endoscopic studies of Barrett's esophagus? A pilot study. Gastrointestinal Endoscopy, 2006, 64, 17-26.	0.5	10
358	Mortality associated with gastroesophageal reflux disease and its non-malignant complications: a systematic review. Scandinavian Journal of Gastroenterology, 2008, 43, 645-653.	0.6	10
359	Risk of Upper Gastrointestinal Cancers in Patients With Gastroesophageal Reflux Disease After a Negative Screening Endoscopy. Clinical Gastroenterology and Hepatology, 2015, 13, 280-286.	2.4	10
360	Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clinical Gastroenterology and Hepatology, 2017, 15, 1965-1967.	2.4	10

#	Article	IF	Citations
361	Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Digestive Diseases and Sciences, 2019, 64, 3328-3336.	1.1	10
362	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Research, 2020, 174, 104698.	1.9	10
363	Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System. Open Forum Infectious Diseases, 2020, 7, ofaa322.	0.4	10
364	Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. Digestive Diseases and Sciences, 2021, 66, 2981-2991.	1.1	10
365	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microbial Ecology, 2021, , 1.	1.4	10
366	Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. International Journal of Molecular Epidemiology and Genetics, 2014, 5, 164-76.	0.4	10
367	Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population. American Journal of Gastroenterology, 2022, 117, 280-287.	0.2	10
368	CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages. Clinical Gastroenterology and Hepatology, 2013, 11, 200-203.	2.4	9
369	Spotlight: COVID-19 PPE and Endoscopy. Gastroenterology, 2020, 159, 759.	0.6	9
370	Associations of Duration, Intensity, and Quantity of Smoking With Risk of Gastric Intestinal Metaplasia. Journal of Clinical Gastroenterology, 2022, 56, e71-e76.	1.1	9
371	Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 294-304.	0.4	9
372	Applying Lean Design Principles to a Gastrointestinal Endoscopy Program for Uninsured Patients Improves Health Care Utilization. Clinical Gastroenterology and Hepatology, 2015, 13, 1556-1559.e4.	2.4	8
373	Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterology Research and Practice, 2019, 2019, 1-5.	0.7	8
374	External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Digestive Diseases and Sciences, 2021, 66, 2387-2393.	1.1	8
375	The epidemic of esophageal adenocarcinoma. Hematology/Oncology Clinics of North America, 2003, 17, 413-432.	0.9	7
376	Bundling in Medicare Patients Undergoing Bidirectional Endoscopy: How Often Does It Happen?. Clinical Gastroenterology and Hepatology, 2014, 12, 58-63.	2.4	7
377	Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. Digestive Diseases and Sciences, 2017, 62, 76-83.	1.1	7
378	Ongoing Alcohol Consumptions Counteracts the Benefits of Sustained Virological Response in Patients with Well Compensated Hepatitis C Cirrhosis: an Observational Study. Annals of Hepatology, 2017, 16, 16-20.	0.6	7

#	Article	IF	Citations
379	Barrettâ€™s esophagus: best practices for treatment and post-treatment surveillance. Annals of Cardiothoracic Surgery, 2017, 6, 75-87.	0.6	7
380	A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prevention Research, 2021, 14, 667-674.	0.7	7
381	Preparing for the NASH epidemic: A call to action. Obesity, 2021, 29, 1401-1412.	1.5	7
382	Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1402-1409.	1.1	7
383	Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. BMC Health Services Research, 2012, 12, 288.	0.9	6
384	Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Review of Gastroenterology and Hepatology, 2013, 7, 493-495.	1.4	6
385	CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages. Gastroenterology, 2013, 144, 478-481.	0.6	6
386	Decision Aids for Shared Decision-Making in Barrett's Esophagus Surveillance. Clinical Gastroenterology and Hepatology, 2015, 13, 91-93.	2.4	6
387	Epidemiology of Hepatocellular Carcinoma. , 2016, , 3-24.		6
388	Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Digestive Diseases and Sciences, 2020, 65, 2691-2699.	1.1	6
389	Risk for Post-Colonoscopy Irritable Bowel Syndrome in Patients With and Without Antibiotic Exposure: A Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e1305-e1322.	2.4	6
390	Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2848-2857.e2.	2.4	6
391	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Scientific Reports, 2022, 12, 5695.	1.6	6
392	The Dawn of a New Era: Transforming Our Domestic Response to Hepatitis B & C. Gastroenterology, 2010, 138, 1225-1230.e3.	0.6	5
393	Improving quality of care in patients with cirrhosis. Clinical Liver Disease, 2013, 2, 123-124.	1.0	5
394	Is Proton Pump Inhibitor Use Associated With Risk of Myocardial Infarction?. Gastroenterology, 2016, 150, 526-527.	0.6	5
395	Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. Digestive Diseases and Sciences, 2021, 66, 1600-1610.	1.1	5
396	A multidisciplinary approach to improving transition readiness in pediatric liver transplant recipients. Pediatric Transplantation, 2021, 25, e13839.	0.5	5

#	Article	IF	Citations
397	Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. International Journal of Molecular Epidemiology and Genetics, 2017, 8, 8-18.	0.4	5
398	Scientific manuscripts: the fun of writing and submitting. Gastrointestinal Endoscopy, 2006, 64, S19-S22.	0.5	4
399	Manuscript writing. Gastrointestinal Endoscopy, 2008, 67, 311-312.	0.5	4
400	Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection. Digestive Diseases and Sciences, 2011, 56, 1835-1847.	1.1	4
401	Dietary Fructose Intake and Severity of Liver Disease in Hepatitis C Virus-infected Patients. Journal of Clinical Gastroenterology, 2013, 47, 545-552.	1.1	4
402	Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. Digestive Diseases and Sciences, 2014, 59, 273-281.	1.1	4
403	Risk Profiles for Barrettâ€™s Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. PLoS ONE, 2016, 11, e0169250.	1.1	4
404	How to Prepare for and Write a Grant: Personal Perspectives. Gastroenterology, 2017, 152, 7-11.	0.6	4
405	Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels. Gastroenterology, 2018, 155, 607-609.	0.6	4
406	Current Status of Chemoprevention in Barrettâ€™s Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 117-130.	0.6	4
407	Prevalence and Predictors of Missed Dysplasia on Index Barrettâ€™s Esophagus Diagnosing Endoscopy in a Veteran Population. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	4
408	A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clinical Gastroenterology and Hepatology, 2022, 20, 1174-1176.	2.4	4
409	Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population. Digestive Diseases and Sciences, 2021, , 1.	1.1	4
410	Clinical and psychosocial variables associated with behavioral intentions to undergo surveillance endoscopy. BMC Gastroenterology, 2014, 14, 107.	0.8	3
411	Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Digestive Diseases and Sciences, 2015, 60, 2030-2037.	1.1	3
412	4 - Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer (HCC) in Non-Alcoholic Fatty Liver Disease (NAFLD). Gastroenterology, 2018, 154, S-1.	0.6	3
413	Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Digestive Diseases and Sciences, 2019, 64, 1470-1477.	1.1	3
414	Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Gastroenterology, 2019, 156, 809-811.	0.6	3

#	Article	IF	Citations
415	Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open Forum Infectious Diseases, 2020, 7, ofaa191.	0.4	3
416	Endoscopic Ultrasound Finding of Diffuse Echogenicity in the Pancreas, Is It Relevant?. Digestive Diseases and Sciences, 2022, 67, 3244-3251.	1.1	3
417	Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population. PLoS ONE, 2021, 16, e0260019.	1.1	3
418	External validation of a model determining risk of neoplastic progression of Barrettâ€™s esophagus in a cohort of U.S. veterans. Gastrointestinal Endoscopy, 2022, 95, 1113-1122.	0.5	3
419	The treatment path in hepatocellular carcinoma. Clinical Advances in Hematology and Oncology, 2017, 15 Suppl 9, 1-20.	0.3	3
420	Racial Differences in the Association Between Adiposity Measures and the Risk of Hepatitis C-related Liver Disease. Journal of Clinical Gastroenterology, 2012, 46, 779-788.	1.1	2
421	Finasteride and Methadone Use and Risk of Advanced Hepatitis C Related Liver Disease. Digestive Diseases and Sciences, 2012, 57, 3004-3010.	1.1	2
422	Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. , 2012, , 142-156.		2
423	The Top Five Reasons You Should Publish in Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 164-165.	2.4	2
424	A Farewell From the Board of Editors of the Blue Journal. Clinical Gastroenterology and Hepatology, 2017, 15, 797-798.	2.4	2
425	Endoscopic ablation of low-grade dysplasia in Barrettâ€™sÂesophagus: Have all the boxes been checked forÂusÂto move on?. Gastrointestinal Endoscopy, 2017, 86, 130-132.	0.5	2
426	Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology, 2018, 68, 7-9.	3.6	2
427	Traditional Chinese Medicine to the rescue of allopathic medicine in the co-adjuvant treatment of hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 97-97.	1.5	2
428	Durability and Effectiveness of Cognitive-Behavioral Therapy for Irritable Bowel Syndrome. Gastroenterology, 2019, 157, 1684-1686.	0.6	2
429	Su1249 â€“ Demographic, Lifestyle and Dietary Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. Gastroenterology, 2019, 156, S-519.	0.6	2
430	The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. Gastroenterology, 2020, 159, 1184-1185.	0.6	2
431	Tenofovir vs. entecavir in reducing hepatocellular carcinoma risk in patients with chronic HBV infection?â€”Still an unsolved question. Hepatobiliary Surgery and Nutrition, 2021, 10, 119-122.	0.7	2
432	Guideline adherence for diagnosis of liver cancer in veterans.. Journal of Clinical Oncology, 2013, 31, 89-89.	0.8	2

#	Article	IF	Citations
433	Inverse Association Between Gluteofemoral Obesity and Risk of Non-Cardia Gastric Intestinal Metaplasia. Clinical Gastroenterology and Hepatology, 2023, 21, 64-71.	2.4	2
434	Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC)Â. Digestive Diseases and Sciences, 0, , .	1.1	2
435	Surveillance for hepatocellular carcinoma: does it work?1. American Journal of Gastroenterology, 2002, 97, 2676-2677.	0.2	1
436	Interferon for Postresection Recurrence of Hepatocellular Carcinoma. American Journal of Gastroenterology, 2002, 97, 3200-3202.	0.2	1
437	Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?. Current Hepatology Reports, 2015, 14, 87-98.	0.4	1
438	The Art and Science of Managing Liver Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 2029-2030.	2.4	1
439	Premature Birth and Large for Gestational Age Are Associated with Risk of Barrettâ€™s Esophagus in Adults. Digestive Diseases and Sciences, 2016, 61, 1139-1147.	1.1	1
440	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 2005-2006.	2.4	1
441	Chemoprevention of Barrettâ€™s oesophagus: a step closer with PPIs and aspirin. Nature Reviews Clinical Oncology, 2018, 15, 728-730.	12.5	1
442	Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1447-1449.	1.9	1
443	Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with Barrettâ€™s esophagus: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2014, 32, 11-11.	0.8	1
444	Advances in the management of hepatocellular carcinoma. Clinical Advances in Hematology and Oncology, 2017, 15 Suppl 9, 2-6.	0.3	1
445	Why Do Small Intraductal Papillary Mucinous Neoplasms Create Such a Huge Management Challenge?. Pancreas, 2022, 51, e13-e15.	0.5	1
446	Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Digestive Diseases and Sciences, 2023, 68, 761-769.	1.1	1
447	Emerging epidemiologic observations in HCV/HIV coinfection. Current Hepatitis Reports, 2006, 5, 162-171.	0.3	0
448	Prevalence and Histological Features of the Gastric Cardia-type Mucosa in Children. Digestive Diseases and Sciences, 2008, 53, 1792-1796.	1.1	0
449	The Risk of Hepatocellular Carcinoma in Patients with Previous Malignancy. Cancer Investigation, 2008, 26, 511-515.	0.6	0
450	Epidemiology of Hepatocellular Carcinoma. , 0, , 409-420.		0

#	Article	IF	Citations
451	Epidemiology of Hepatocellular Carcinoma. , 2009, , 1-25.		0
452	Response to Braillon. American Journal of Gastroenterology, 2013, 108, 1931.	0.2	0
453	Weight Change and Weight Cycling AreÂNotÂAssociated With Risk of Barrettâ€™sÂEsophagus. Clinical Gastroenterology and Hepatology, 2016, 14, 1839-1840.	2.4	0
454	Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 1823-1827.	2.4	0
455	Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. Clinical Gastroenterology and Hepatology, 2017, 15, 137-139.	2.4	0
456	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 2004.	2.4	0
457	Prospective implementation of algorithmic patient selection for gastrostomy tube placement consultations: a pre- and post-intervention analysis . Clinical and Experimental Gastroenterology, 2019, Volume 12, 231-237.	1.0	0
458	Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 1912-1914.	2.4	0
459	Our New Presidentâ€”John M. Inadomi, MD, AGAF. Gastroenterology, 2021, 160, 2149-2154.	0.6	0
460	Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. Gastroenterology, 2021, 161, 333-335.	0.6	0
461	Epidemiology of Hepatocellular Carcinoma. , 2010, , 51-73.		0
462	Utilization and outcomes of primary tumor surgery for stage IV colon cancer in the United States: A population-based study.. Journal of Clinical Oncology, 2012, 30, 3542-3542.	0.8	0
463	The effect of gaps in chemotherapy in patients with stage IV colorectal cancer.. Journal of Clinical Oncology, 2013, 31, e17501-e17501.	0.8	0
464	Risk Factors for Hepatocellular Carcinoma: A Historical Perspective. Clinical Liver Disease, 2021, 18, 1-13.	1.0	0
465	Authorsâ€™ response to Letter to the Editor from Liu and Li regarding Risk for post-colonoscopy irritable bowel syndrome in patients with and without antibiotic exposure.. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
466	Gastroesophageal Reflux and the Obesity Epidemic. Gastroenterology and Hepatology, 2006, 2, 795-796.	0.2	0
467	Reply. Hepatology, 2022, 76, E50-E50.	3.6	0